Skip to content
The Nexus
DossierENTITY

ENDO 2026

Coverage of ENDO 2026 in the Nexus archive.

Earliest in view: Jun 20 · 13:00 UTCMost recent: Jul 28 · 17:50 UTC
Co-mentioned in this coverage
Endocrine Societyorganization1hypercortisolismtopic1cardiometabolic healthtopic1GLP-1 medicationstopic1hypothalamic-pituitary-gonadal (HPG) axistopic1functional hypogonadismtopic1dulaglutidetopic1liraglutidetopic1semaglutidetopic1Anthony Puopoloperson1RexMDorganization1
Recent coverage
  • HEALTHJul 28 · 17:50 UTCMEDPAGE TODAY
    Future Studies Could Expand the Reach of Hypercortisolism Treatment

    Experts at ENDO 2026, the Endocrine Society's annual meeting, discussed expanding hypercortisolism treatment beyond Cushing syndrome to address broader cardiometabolic health implications.

  • HEALTHJun 20 · 13:00 UTCFOX NEWS
    Popular weight-loss drugs linked to unexpected male fertility benefit

    GLP-1 weight-loss drugs may improve male fertility by enhancing testosterone levels and semen quality in obese men with low testosterone. A review of five trials found no suppression of male reproductive hormones and potential benefits for metabolic health, though more research is needed.